Horizon Europe – Cluster Health 2025 Single Stage (13 Calls)

Tackling diseases and reducing disease burden (Single stage-2025)

• HORIZON-HLTH-2025-01-DISEASE-01: Testing safety and efficacy of phage therapy for the treatment of antibiotic-resistant bacterial infections.
• HORIZON-HLTH-2025-01-DISEASE-03: Development of antibodies and antibody-derived proteins for the prevention and treatment of infectious diseases with epidemic potential.
• HORIZON-HLTH-2025-01-DISEASE-04: Leveraging artificial intelligence for pandemic preparedness and response.
• HORIZON-HLTH-2025-01-DISEASE-05: Support for the functioning of the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R).
• HORIZON-HLTH-2025-01-DISEASE-06: Implementation research addressing strategies to strengthen health systems for equitable high-quality care and health outcomes in the context of non-communicable diseases (GACD).
• HORIZON-HLTH-2025-01-DISEASE-07: Tackling high-burden for patients and under-researched medical conditions.

Ensuring equal access to innovative, sustainable, and high-quality healthcare (Single stage-2025)

• HORIZON-HLTH-2025-01-CARE-01: Testing safety and efficacy of phage therapy for the treatment of antibiotic-resistant bacterial infections.

Developing and using new tool, technologies and digital solutions for a healthy society (Single stage 2025)

• HORIZON -HLTH-2025-01-TOOL-01: Enhancing cell therapies with genomic techniques.
• HORIZON -HLTH-2025-01-TOOL-02: Advancing cell secretome-based therapies
• HORIZON -HLTH-2025-01-TOOL-03: Leveraging multimodal data to advance Generative Artificial Intelligence applicability in biomedical research (GenAI4EU).
• HORIZON -HLTH-2025-01-TOOL-05: Boosting the translation of biotech research into innovative health therapies.

Maintaining an innovative, sustainable, and competitive EU health industry (Single stage 2025)

• HORIZON -HLTH-2025-01-IND-01: Optimising the manufacturing of Advanced Therapy Medicinal Products (ATMPs).
• HORIZON -HLTH-2025-01-IND-02: Digitalisation of conformity assessment procedures of medical devices and in vitro diagnostic medical devices.

Deadline: September 16, 2025.